Clinical trials: Nephropathy, Diabetic
Diabetes Mellitus, Type 2, Diabetic Nephropathy
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage…
- Trial name
- CREDENCE (NCT02065791)
- Testing
- Canagliflozin
- Where
- 575 sites in United States, Argentina and 32 more
- Volunteers
- 4,401 people
- Sponsor
- Janssen Research & Development, LLC
Diabetic Nephropathy
Study of LY3016859 in Participants With Diabetic Nephropathy
The purpose of this two-part study is to investigate the safety, tolerability and efficacy of LY3016859 after multiple intravenous (IV) dosing's in participants with diabetic nephropathy (DN).
- Trial name
- NCT01774981
- Testing
- LY3016859
- Where
- 7 sites in United States, Bulgaria
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Diabetic Nephropathy
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.
- Trial name
- NCT01712061
- Testing
- PF-04634817
- Where
- 142 sites in United States, Argentina and 12 more
- Volunteers
- 226 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.
- Trial name
- NCT04515849
- Testing
- Cotadutide 100 micrograms, Cotadutide 300 micrograms, Cotadutide 600 micrograms
- Where
- 83 sites in Australia, Canada and 6 more
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease
Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function
The hypothesis of the current proposal is that chronic pioglitazone therapy will result in improved endothelial function, decreased inflammation, and preservation of renal function in patients with CKD but without diabetes.
- Trial name
- NCT00586261
- Testing
- Pioglitazone, Nitroglycerin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
CKD, Diabetic Kidney Disease
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or…
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity
- Trial name
- RAISE-KT (NCT04741074)
- Testing
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Geisinger Clinic
Type1diabetes, Type1 Diabetes Mellitus
Evaluation of Coffee Therapy for Improvement of Renal Oxygenation
Over 1.25 million Americans have Type 1 Diabetes (T1D), increasing risk for early death from cardiovascular disease (CVD). Despite advances in glycemic and blood pressure control, a child diagnosed with T1D is expected to live up…
- Conditions
- Type1diabetes, Type1 Diabetes Mellitus, Diabetic Kidney Disease, Juvenile Diabetes
- Trial name
- COFFEE (NCT03878277)
- Testing
- Starbucks® Cold brew - 325ml bottle
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Diabetic Nephropathy
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
This Phase 2A study is an adaptive design pilot study investigating the efficacy and safety of daily Acthar administration in diabetic patients with nephropathy and proteinuria.
- Trial name
- NCT01601236
- Testing
- Repository Corticotropin Injection
- Where
- 10 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mallinckrodt
Chronic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to…
- Trial name
- FIDELIO-DKD (NCT02540993)
- Testing
- Finerenone (BAY94-8862)
- Where
- 978 sites in United States, Argentina and 46 more
- Volunteers
- 5,734 people
- Sponsor
- Bayer
Chronic Kidney Disease
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
- Trial name
- NCT04492722
- Testing
- AZD5718, Dapagliflozin 10 mg
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Type 2 Diabetic Nephropathy
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845…
- Trial name
- NCT01488877
- Testing
- PF-03882845, Spironolactone
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pfizer
ESRD, Diabetes
IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
Primary Objective: To demonstrate that use of glucose sparing prescriptions (PEN vs Dianeal only) in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD)patients…
- Conditions
- ESRD, Diabetes, CAPD, APD
- Trial name
- Impendia (NCT00567489)
- Testing
- Physioneal, Dianeal, Extraneal
- Where
- 19 sites in Hong Kong, Russia and 3 more
- Volunteers
- 137 people
- Sponsor
- Vantive Health LLC
Kidney Disease, Nephropathy
VA NEPHRON-D: Diabetes iN Nephropathy Study
Diabetes is the leading cause of end-stage renal disease (ESRD) in the United States. The overall rate of ESRD secondary to diabetes has risen 68% since 1992.
- Conditions
- Kidney Disease, Nephropathy, Type 2 Diabetes
- Trial name
- VA NEPHRON-D (NCT00555217)
- Testing
- losartan, lisinopril
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 1,448 people
- Sponsor
- US Department of Veterans Affairs
Type 2 Diabetes, Diabetes Type 2
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
The current protocol plans to enroll participants with youth-onset Type 2 Diabetes (T2D) as well as obese and lean controls from the Renal-HEIR - Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2…
- Conditions
- Type 2 Diabetes, Diabetes Type 2, Diabetic Nephropathies, Nephropathy
- Trial name
- HEIRitage (NCT05530356)
- Testing
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2, Diabetic Nephropathies
Renoprotective Effects of Dapagliflozin in Type 2 Diabetes
Background: Worldwide, diabetic nephropathy or Diabetic Kidney Disease (DKD), is the most common cause of chronic and end-stage kidney disease.
- Trial name
- RED (NCT02682563)
- Testing
- Dapagliflozin 10mg QD, Gliclazide 30mg QD
- Where
- Netherlands
- Volunteers
- 44 people
- Sponsor
- M.H.H. Kramer
Diabetic Nephropathy
Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy
The purpose of this study is to evaluate the effect of lipo-prostaglandin E1 （lipo-PGE1) on renal oxygenation in patients with diabetic nephropathy by blood oxygenation level dependent magnetic resonance imaging…
- Trial name
- NCT02628106
- Testing
- Lipo-PGE1
- Where
- China
- Volunteers
- 21 people
- Sponsor
- West China Hospital
Diabetes
Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or fish oil (1 gram of omega-3 fatty…
- Trial name
- VITAL-DKD (NCT01684722)
- Testing
- Vitamin D, Omega-3 fatty acids (fish oil)
- Where
- United States
- Volunteers
- 1,312 people
- Sponsor
- University of Washington
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just completed an 8 month trial of MMF treatment alone.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446251
- Testing
- Rituximab, Mycophenolate mofetil (MMF)
- Volunteers
- 14 people
- Sponsor
- University of Washington
Diabetic Nephropathy, Type 2 Diabetes Mellitus
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.
- Conditions
- Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria
- Trial name
- NCT00141453
- Testing
- olmesartan medoxomil
- Where
- 2 sites in China, Japan
- Volunteers
- 577 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetic Nephropathies
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy.
- Trial name
- ARTS-DN (NCT01874431)
- Testing
- Finerenone (BAY94-8862)
- Where
- 147 sites in United States, Australia and 21 more
- Volunteers
- 823 people
- Sponsor
- Bayer